Randomized, Open-Label, Single Dose, 3 Period, Crossover Evaluation of the Relative Bioavailability of Two Experimental Fixed-Dose Combination Tablet Formulations of Dolutegravir 50 mg/Abacavir 600 mg/Lamivudine 300 mg Compared to Co administered Dolutegravir 50 mg and Epzicom (Abacavir 600 mg/Lamivudine 300 mg) Tablets in Healthy Adult Subjects.

Trial Profile

Randomized, Open-Label, Single Dose, 3 Period, Crossover Evaluation of the Relative Bioavailability of Two Experimental Fixed-Dose Combination Tablet Formulations of Dolutegravir 50 mg/Abacavir 600 mg/Lamivudine 300 mg Compared to Co administered Dolutegravir 50 mg and Epzicom (Abacavir 600 mg/Lamivudine 300 mg) Tablets in Healthy Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Oct 2015

At a glance

  • Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Dolutegravir; Lamivudine/abacavir
  • Indications HIV infections
  • Focus Pharmacokinetics
  • Sponsors ViiV Healthcare
  • Most Recent Events

    • 04 Aug 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top